Chiron Corporation

Onyx Pharmaceuticals, Inc.

The University of North Carolina at Chapel Hill

Roche Molecular Systems, Inc.

Cetus Oncology Corporation

Cetus Onocology Corporation

Chiron Corporation/chapel Hill North Carolina

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

George A Martin

Kirston E Koths

Robert F Halenbeck

Ernest S Kawasaki

Martha B Ladner

Mazie Yee Coyne

Peter Ralph

John Stephen Haskill

Arie Abo

Janelle A Noble

Danute E Nitecki

Janelle N Van Arsdell

James W Larrick

Bonnee Rubinfeld

Francis P McCormick

Steven A Soper

Gail L Wong

Robin Clark

Michael Piatak

Jen Jen Yeh

Makgorzata Witek

Edward C O'Rourke

Steven Soper

This invention provides methods and compositions for capturing circulating tumor cells (CTCs) as well as various divergent CTC phenotypes using seprase-specific affinity reagents. Methods of analyzing CTCs and assessing their metastatic potential in vivo and in vitro are also disclosed.

In Vitro capture and analysis of circulating tumor cells

In vitro capture and analysis of circulating tumor cells

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both &ldquo;long&rdquo; and &ldquo;short&rdquo; forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

DNA encoding N&nabla;2 CSF-1 (short form) and carboxy truncated fragment thereof

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

DNA encoding NV2 (long form) and carboxy truncated fragments thereof

N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof

N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof

A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

Human PAK65

Multifunctional proteins having M-CSF activity and at least one other bioactivity not found together in a single naturally occuring molecule are described. These multifunctional M-CSF proteins can be produced by the expression of fused genes which are also described. These multifunctional M-CSF proteins have increased therapeutic potential.

Multifunctional M-CSF proteins and genes encoding therefor

A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac 1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro .beta. and .gamma., and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.

Gro genes

Gro genes, proteins, and uses thereof

Method of purifying Gro .beta. or Gro .alpha. protein using antibodies

The present invention is directed to DNA, host cells and a vector encoding a protein with cytokine inhibitory activity, particularly IL-1 inhibitory activity. The protein encoded by the DNA of the present invention is particularly useful as an IL-1 antagonist.

DNA, host cell and vector encoding a protein with cytokine inhibitory

Growing community of inventors

Berkeley, CA, United States of America

George A Martin